Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Early Switching to Dolutegravir/Lamivudine (DTG/3TC) From INSTI-based Three-drug Regimens in HIV-1-infected Adults Previously naïve Who Achieve Virological Suppression

NCT04979468 is registered in ClinicalTrials.gov with Societa' Italiana Di Malattie Infettive E Tropicali as lead sponsor.

NCT NCT04979468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04979468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Early Switching to Dolutegravir/Lamivudine (DTG/3TC) From INSTI-based Three-drug Regimens in HIV-1-infected Adults Previously naïve Who Achieve Virological Suppression
Lead sponsor
Societa' Italiana Di Malattie Infettive E Tropicali
Phase
Phase 3
Overall status
Unknown status
Start date
March 23, 2021
Completion date
April 1, 2024
Enrollment
440 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection